{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=30", "query": { "intervention": "FAST alone", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 1359, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T16:56:03.174Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05216354", "title": "Fruquintinib Renal Impairment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2022-03-11", "completion_date": "2023-06-26", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216354" }, { "nct_id": "NCT00778024", "title": "Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "fluoxetine HCL 40 mg capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2003-08", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2009-12-15", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778024" }, { "nct_id": "NCT03357796", "title": "Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "LY03005", "type": "DRUG" }, { "name": "Pristiq", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Luye Pharma Group Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2017-11-27", "completion_date": "2017-12-22", "has_results": false, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Eatontown, New Jersey", "locations": [ { "city": "Eatontown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03357796" }, { "nct_id": "NCT00865059", "title": "A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Gabapentin 800 mg Tablets, single dose", "type": "DRUG" }, { "name": "NEURONTIN® 800 mg Tablets, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2001-02", "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2010-08-17", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865059" }, { "nct_id": "NCT05701189", "title": "Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Guillain-Barre Syndrome" ], "interventions": [ { "name": "Efgartigimod Alfa-Fcab", "type": "DRUG" }, { "name": "Intravenous Immunoglobulin (IVIg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chafic Karam", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-09-10", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05701189" }, { "nct_id": "NCT00899470", "title": "Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Co-administration of Saxagliptin and Metformin IR, Fasted", "type": "DRUG" }, { "name": "Saxagliptin/Metformin, Fasting", "type": "DRUG" }, { "name": "Co-administration of Saxagliptin and Metformin IR, Fed", "type": "DRUG" }, { "name": "Saxagliptin/Metformin, Fed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "19 Years to 45 Years" }, "enrollment_count": 24, "start_date": "2009-06", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2015-06-01", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899470" }, { "nct_id": "NCT00363051", "title": "Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Islet Cell Carcinoma", "Neuroendocrine Carcinoma", "Neuroendocrine Tumor", "Pancreatic Neoplasms" ], "interventions": [ { "name": "Everolimus 10 mg", "type": "DRUG" }, { "name": "Octreotide Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2006-06", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-05-10", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363051" }, { "nct_id": "NCT04560556", "title": "Linking Persons With HIV, Discharged From Jail, With Community Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Point-of-Care (POC) Rapid HIV Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Fourth Generation Antigen/antibody (Ag/Ab) HIV Test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2020-11-10", "completion_date": "2021-11-24", "has_results": false, "last_update_posted_date": "2022-05-23", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560556" }, { "nct_id": "NCT06741761", "title": "12-hour Time Limited Feeding in Critical Care", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Critical Illness" ], "interventions": [ { "name": "12-hour time-restricted feeding (TRF12)", "type": "OTHER" }, { "name": "Continuous 24 hour feeding (CONT24).", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-03-25", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06741761" }, { "nct_id": "NCT06938555", "title": "The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer Survivor", "Cancer Related Cognitive Difficulties", "Sleep", "Quality of Life" ], "interventions": [ { "name": "Prolonged Nightly Fasting", "type": "BEHAVIORAL" }, { "name": "Health Education Videos", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-03-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-25T16:56:03.174Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06938555" } ] }